161 related articles for article (PubMed ID: 33782292)
1. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Has Simsek D; Civan C; Erdem S; Sanli Y
Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292
[TBL] [Abstract][Full Text] [Related]
2. Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma.
Sasikumar A; Joy A; Nanabala R; Unni M; Tk P
Clin Nucl Med; 2016 Dec; 41(12):e517-e519. PubMed ID: 27749421
[TBL] [Abstract][Full Text] [Related]
3. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?
Can C; Gündoğan C; Kömek H
Clin Nucl Med; 2021 Apr; 46(4):e233-e235. PubMed ID: 33031232
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT.
Civan C; Isik EG; Simsek DH
Clin Nucl Med; 2021 Apr; 46(4):e212-e213. PubMed ID: 33156050
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
6. Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT.
Weitzer F; Nazerani-Hooshmand T; Aigner RM; Pernthaler B
Clin Nucl Med; 2021 Jul; 46(7):e358-e359. PubMed ID: 34081054
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell Carcinoma.
Chen EJ; Tan TH; Chew MT; Chye PC
Clin Nucl Med; 2020 Jul; 45(7):e317-e319. PubMed ID: 32404702
[TBL] [Abstract][Full Text] [Related]
10. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake.
Jochumsen MR; Gormsen LC; Nielsen GL
Clin Nucl Med; 2018 Feb; 43(2):117-119. PubMed ID: 29261620
[TBL] [Abstract][Full Text] [Related]
12.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-Prostate-Specific Membrane Antigen-Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET/CT.
Uijen MJM; Weijers JAM; Driessen CML; van Herpen CML; Nagarajah J
Clin Nucl Med; 2022 Feb; 47(2):140-141. PubMed ID: 35006109
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. PET/CT With 68Ga-PSMA and 18F-FDG in Metastatic Adenoid Cystic Carcinoma: Report of 2 Cases.
Isgoren S; Hekimsoy T; Koroglu E; Demir H
Clin Nucl Med; 2022 May; 47(5):e423-e424. PubMed ID: 35234196
[TBL] [Abstract][Full Text] [Related]
16. Synergic role of dual tracer PET/CT with
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Ruffini L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):322-324. PubMed ID: 36100315
[No Abstract] [Full Text] [Related]
17. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes.
Oflas M; Ozluk Y; Sanli O; Ozkan ZG; Kuyumcu S
Clin Nucl Med; 2022 Jan; 47(1):e45-e46. PubMed ID: 34284482
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
